Φορτώνει......
Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30‐positive aggressive lymphomas
OBJECTIVES: A treatment regimen consisting of bendamustine and brentuximab vedotin (BV) has been described as a highly potent salvage therapy and as an effective induction therapy leading to high response rates before autologous stem cell transplantation (ASCT) in patients with classical Hodgkin lym...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Eur J Haematol |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
John Wiley and Sons Inc.
2020
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7065019/ https://ncbi.nlm.nih.gov/pubmed/31838747 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ejh.13368 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|